M. Lichinitser

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Yu Jeong Bang, Eduardo Yañez Ruiz, Eric Van Cutsem et al. · Annals of Oncology · 2018 · 503 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

Richard J. Gralla, M. Lichinitser, S. van der Vegt et al. · Annals of Oncology · 2003 · 471 citations

Medicine, Oncology, Pharmacology +17

Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869

Simon Van Belle, M. Lichinitser, Rudolph M. Navari et al. · Cancer · 2002 · 148 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer

Leonard B. Saltz, Stephen Clarke, Eduardo Díaz‐Rubio et al. · Journal of Clinical Oncology · 2007 · 114 citations

Medicine, Oncology, Pharmacology +12